BR112014004352A2 - anticorpos anti-xcr1 humano - Google Patents

anticorpos anti-xcr1 humano

Info

Publication number
BR112014004352A2
BR112014004352A2 BR112014004352A BR112014004352A BR112014004352A2 BR 112014004352 A2 BR112014004352 A2 BR 112014004352A2 BR 112014004352 A BR112014004352 A BR 112014004352A BR 112014004352 A BR112014004352 A BR 112014004352A BR 112014004352 A2 BR112014004352 A2 BR 112014004352A2
Authority
BR
Brazil
Prior art keywords
human xcr1
xcr1 antibodies
antibodies
amino acids
binds
Prior art date
Application number
BR112014004352A
Other languages
English (en)
Portuguese (pt)
Inventor
Nishimura Miyuki
Imai Toshio
Kawano Tetsu
Sawa Yukihisa
Sakamoto Yoshimasa
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of BR112014004352A2 publication Critical patent/BR112014004352A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112014004352A 2011-09-01 2012-08-30 anticorpos anti-xcr1 humano BR112014004352A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161530194P 2011-09-01 2011-09-01
US201261659637P 2012-06-14 2012-06-14
PCT/JP2012/072667 WO2013032032A1 (en) 2011-09-01 2012-08-30 Anti-human xcr1 antibodies

Publications (1)

Publication Number Publication Date
BR112014004352A2 true BR112014004352A2 (pt) 2017-03-21

Family

ID=46881120

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014004352A BR112014004352A2 (pt) 2011-09-01 2012-08-30 anticorpos anti-xcr1 humano

Country Status (19)

Country Link
US (1) US9371389B2 (https=)
EP (1) EP2751140B1 (https=)
JP (1) JP5989096B2 (https=)
KR (1) KR101767717B1 (https=)
CN (1) CN103764680B (https=)
AR (1) AR087749A1 (https=)
AU (1) AU2012302596B2 (https=)
BR (1) BR112014004352A2 (https=)
CA (1) CA2846370C (https=)
ES (1) ES2684173T3 (https=)
HK (1) HK1199038A1 (https=)
IL (1) IL231075A (https=)
IN (1) IN2014CN01466A (https=)
MX (1) MX346560B (https=)
MY (1) MY166152A (https=)
PH (1) PH12014500384A1 (https=)
RU (1) RU2619180C2 (https=)
TW (1) TWI563004B (https=)
WO (1) WO2013032032A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10071170B2 (en) 2013-06-24 2018-09-11 Ablbio Antibody-drug conjugate having improved stability and use thereof
RS63482B1 (sr) * 2015-08-05 2022-09-30 Acticor Biotech Nova anti-humana gpvi antitela i njihove upotrebe
TWI866194B (zh) 2017-02-03 2024-12-11 法商艾提寇生物技術公司 使用抗人類ｇｐｖｉ抗體抑制血小板凝集
WO2018146074A1 (en) 2017-02-07 2018-08-16 Vib Vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
CN107312092B (zh) * 2017-05-04 2020-12-11 华南农业大学 一种斜带石斑鱼ccr12的多克隆抗体制备方法及其应用
US20210130776A1 (en) * 2017-09-29 2021-05-06 The Broad Institute, Inc. Methods and compositions for modulating suppression of lymphocyte activity
EP3743448A4 (en) * 2018-01-26 2021-11-03 Orionis Biosciences, Inc. XCR1 BINDING AGENTS AND USES THEREOF
US12410225B2 (en) 2018-11-08 2025-09-09 Orionis Biosciences, Inc Modulation of dendritic cell lineages
US20220073630A1 (en) 2018-12-28 2022-03-10 Hoffmann-La Roche, Inc. A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5786210A (en) 1994-02-08 1998-07-28 Schering Corporation Mammalian thymokine genes
AU2001250412A1 (en) * 2000-03-31 2001-10-08 Ipf Pharmaceuticals Gmbh Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using specific chemokine receptor analysis and the chemokine receptor-ligand interaction
WO2002059608A2 (en) 2000-11-29 2002-08-01 Lifespan Biosciences, Inc. Compositions and methods related to chemokine (c motif) xc receptor 1 (ccxcr1)
US20050136033A9 (en) 2002-08-13 2005-06-23 Matthias Mack Method of treating allergen induced airway disease
WO2004072646A1 (en) * 2003-02-13 2004-08-26 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 5 (gpr5)
EP1698902A1 (en) * 2005-03-01 2006-09-06 DKFZ Deutsches Krebsforschungszentrum Use of XCR1 for diagnosing or monitoring of immune tolerance
CN101293924A (zh) 2007-04-24 2008-10-29 上海国健生物技术研究院 骨桥蛋白的功能表位、与其特异性结合的单克隆抗体及其在制备抗肿瘤转移药物中的用途
EP2062592A1 (en) * 2007-11-20 2009-05-27 BUNDESREPUBLIK DEUTSCHLAND letztvertreten durch das Robert Koch-Institut vertreten durch seinen Präsidenten System for delivery into a XCR1 positive cell and uses thereof
KR20110128876A (ko) * 2009-02-16 2011-11-30 바이오렉스 쎄라퓨틱스, 인코포레이티드 인간화된 항-ｃｄ20 항체 및 이용 방법

Also Published As

Publication number Publication date
ES2684173T3 (es) 2018-10-01
IN2014CN01466A (https=) 2015-05-08
PH12014500384A1 (en) 2014-04-14
IL231075A (en) 2017-08-31
HK1199038A1 (en) 2015-06-19
RU2619180C2 (ru) 2017-05-12
JP5989096B2 (ja) 2016-09-07
AR087749A1 (es) 2014-04-16
EP2751140A1 (en) 2014-07-09
US20140193421A1 (en) 2014-07-10
WO2013032032A1 (en) 2013-03-07
EP2751140B1 (en) 2018-05-30
NZ621320A (en) 2015-11-27
IL231075A0 (en) 2014-03-31
KR101767717B1 (ko) 2017-08-11
TW201311725A (zh) 2013-03-16
AU2012302596B2 (en) 2016-12-01
MX346560B (es) 2017-03-24
MY166152A (en) 2018-06-06
US9371389B2 (en) 2016-06-21
AU2012302596A1 (en) 2014-03-06
CA2846370A1 (en) 2013-03-07
JP2014527396A (ja) 2014-10-16
CN103764680B (zh) 2016-11-23
MX2014002078A (es) 2014-05-30
KR20140054108A (ko) 2014-05-08
CA2846370C (en) 2019-04-23
TWI563004B (en) 2016-12-21
RU2014106832A (ru) 2015-08-27
CN103764680A (zh) 2014-04-30

Similar Documents

Publication Publication Date Title
BR112014004352A2 (pt) anticorpos anti-xcr1 humano
BR112014005644A2 (pt) anticorpo anti-alfabetatcr
UA115439C2 (uk) Гуманізоване антитіло, яке розпізнає альфа-синуклеїн
MX2021011167A (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
NZ607969A (en) Cd33 binding agents
CY1120398T1 (el) Ανθρωποποιημενα αντισωματα που αναγνωριζουν αλφα-συνουκλεϊνη
UA113623C2 (uk) Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi)
BR112016013347A2 (pt) anticorpo monoclonal humano neutralizante anti-il-33
UA117097C2 (uk) Антитіло проти лігандів рецептора в1 брадикініну
BR112013033258A8 (pt) Anticorpo isolado ou fragmento de ligação ao antígeno do mesmo que se liga a alfa-sinucleína, composição e seus usos
PE20141162A1 (es) Anticuerpos anti-il-23
NZ597023A (en) Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same
UA111818C2 (uk) Антитіло проти csf-1r
SG195073A1 (en) Deimmunized serum-binding domains and their use for extending serum half-life
UA116873C2 (uk) Антитіло, яке зв'язується з ox40
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
EA201070539A1 (ru) НОВЫЕ АНТИТЕЛА, СПЕЦИФИЧНЫЕ К β-АМИЛОИДНЫМ ПЕПТИДАМ, И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ДИАГНОСТИЧЕСКИХ ИЛИ ЛЕКАРСТВЕННЫХ СРЕДСТВ
BR112014025560A2 (pt) anticorpos anti-pdgf-c
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
MX388698B (es) Moleculas de enlace, especialmente anticuerpos, enlazadas a l1cam(cd171).
BR112014027991A2 (pt) agentes para neutralização de influenza
MA38161A1 (fr) Anticorps anti-bmp-6
JO3188B1 (ar) بروتينات رابطة لمولد الضد محددة لمكون p لنظير النشا بالمصل
UA117657C2 (uk) Антитіло до трансглютамінази 2 (tg2)
EA201270701A1 (ru) Ингибирующие металлопротеины антитела

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements